KR20170020204A - Composition for Preventing, Improving, or Treating of Th1-mediated Immune Disease, Th17-mediated Immune Disease, or Th2-mediated Immune Disease Comprising Extracts from Lactobacillus pentosus as an Active Ingredients - Google Patents
Composition for Preventing, Improving, or Treating of Th1-mediated Immune Disease, Th17-mediated Immune Disease, or Th2-mediated Immune Disease Comprising Extracts from Lactobacillus pentosus as an Active Ingredients Download PDFInfo
- Publication number
- KR20170020204A KR20170020204A KR1020160026193A KR20160026193A KR20170020204A KR 20170020204 A KR20170020204 A KR 20170020204A KR 1020160026193 A KR1020160026193 A KR 1020160026193A KR 20160026193 A KR20160026193 A KR 20160026193A KR 20170020204 A KR20170020204 A KR 20170020204A
- Authority
- KR
- South Korea
- Prior art keywords
- mediated immune
- immune disease
- strain
- disease
- lactobacillus pentosus
- Prior art date
Links
- 241000186684 Lactobacillus pentosus Species 0.000 title claims abstract description 115
- 230000001404 mediated effect Effects 0.000 title claims abstract description 90
- 208000026278 immune system disease Diseases 0.000 title claims abstract description 87
- 239000000203 mixture Substances 0.000 title claims abstract description 84
- 239000004480 active ingredient Substances 0.000 title claims abstract description 14
- 239000000284 extract Substances 0.000 title description 4
- 208000026935 allergic disease Diseases 0.000 claims abstract description 25
- 108010065805 Interleukin-12 Proteins 0.000 claims abstract description 8
- 102000013462 Interleukin-12 Human genes 0.000 claims abstract description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 5
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 39
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 18
- 210000003289 regulatory T cell Anatomy 0.000 claims description 16
- 210000002707 regulatory b cell Anatomy 0.000 claims description 13
- 239000002537 cosmetic Substances 0.000 claims description 10
- 230000016396 cytokine production Effects 0.000 claims description 10
- 235000013376 functional food Nutrition 0.000 claims description 9
- 230000036541 health Effects 0.000 claims description 9
- 235000021109 kimchi Nutrition 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 230000031261 interleukin-10 production Effects 0.000 claims description 5
- 230000003449 preventive effect Effects 0.000 claims description 5
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 4
- 229940117681 interleukin-12 Drugs 0.000 claims description 3
- 230000008944 intestinal immunity Effects 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 abstract description 67
- 108090000695 Cytokines Proteins 0.000 abstract description 67
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 24
- 230000028327 secretion Effects 0.000 abstract description 22
- 230000007815 allergy Effects 0.000 abstract description 17
- 230000002401 inhibitory effect Effects 0.000 abstract description 16
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 14
- 230000001939 inductive effect Effects 0.000 abstract description 13
- 206010061218 Inflammation Diseases 0.000 abstract description 10
- 230000004054 inflammatory process Effects 0.000 abstract description 10
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 9
- 208000027866 inflammatory disease Diseases 0.000 abstract description 9
- 230000036039 immunity Effects 0.000 abstract description 7
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 6
- 108090000174 Interleukin-10 Proteins 0.000 abstract description 3
- 102000003814 Interleukin-10 Human genes 0.000 abstract description 3
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 32
- 206010012438 Dermatitis atopic Diseases 0.000 description 31
- 201000008937 atopic dermatitis Diseases 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
- 201000010099 disease Diseases 0.000 description 27
- 230000000694 effects Effects 0.000 description 25
- 230000001965 increasing effect Effects 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 210000004443 dendritic cell Anatomy 0.000 description 21
- 239000006041 probiotic Substances 0.000 description 21
- 235000018291 probiotics Nutrition 0.000 description 21
- 102000004388 Interleukin-4 Human genes 0.000 description 19
- 108090000978 Interleukin-4 Proteins 0.000 description 19
- 210000001165 lymph node Anatomy 0.000 description 19
- 238000000034 method Methods 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 14
- 210000002865 immune cell Anatomy 0.000 description 13
- 230000006698 induction Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 230000002265 prevention Effects 0.000 description 12
- -1 tracant Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 208000004262 Food Hypersensitivity Diseases 0.000 description 11
- 230000000172 allergic effect Effects 0.000 description 11
- 235000020932 food allergy Nutrition 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 206010003645 Atopy Diseases 0.000 description 10
- 108090000176 Interleukin-13 Proteins 0.000 description 10
- 102000013691 Interleukin-17 Human genes 0.000 description 10
- 108050003558 Interleukin-17 Proteins 0.000 description 10
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 10
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 10
- 230000003266 anti-allergic effect Effects 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 206010012442 Dermatitis contact Diseases 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 238000010172 mouse model Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 206010016946 Food allergy Diseases 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 210000000068 Th17 cell Anatomy 0.000 description 7
- 208000010668 atopic eczema Diseases 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 208000010247 contact dermatitis Diseases 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 206010057190 Respiratory tract infections Diseases 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 6
- 239000013566 allergen Substances 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 5
- 210000000447 Th1 cell Anatomy 0.000 description 5
- 210000004241 Th2 cell Anatomy 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 208000002029 allergic contact dermatitis Diseases 0.000 description 5
- 208000003455 anaphylaxis Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 206010039085 Rhinitis allergic Diseases 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 201000010105 allergic rhinitis Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010061557 Allergic otitis media Diseases 0.000 description 3
- 206010052748 Bacterial allergy Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 3
- 206010013700 Drug hypersensitivity Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000012404 In vitro experiment Methods 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229960004784 allergens Drugs 0.000 description 3
- 208000002205 allergic conjunctivitis Diseases 0.000 description 3
- 201000010435 allergic urticaria Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 208000024998 atopic conjunctivitis Diseases 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000019734 interleukin-12 production Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 241000238876 Acari Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 101001066288 Gallus gallus GATA-binding factor 3 Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical class NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000029662 T-helper 1 type immune response Effects 0.000 description 2
- 230000030429 T-helper 17 type immune response Effects 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000036732 histological change Effects 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000006057 immunotolerant effect Effects 0.000 description 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000029069 type 2 immune response Effects 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101001033265 Mus musculus Interleukin-10 Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 206010057244 Post viral fatigue syndrome Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 108091008680 RAR-related orphan receptors Proteins 0.000 description 1
- 108091008778 RORγ2 Proteins 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008970 bacterial immunity Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003550 mucous cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A23Y2220/65—
-
- C12R1/225—
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
The present invention relates to a novel Lactobacillus pentosus KF340 strain (Accession No. KCCM 11675P) and a method for the prevention of a Th1-mediated immune disease, a Th17-mediated immune disease, or a Th2-mediated immune disease , ≪ / RTI >
Recently, the meta genome project to identify intestinal microflora in the United States has revealed the correlation between the distribution of intestinal microflora and various immune system diseases including allergies. Thus, the distribution and diversity of intestinal bacteria and intestinal immunity are closely related to the immune system.
Looking at the market size of probiotics, the world probiotic market size is estimated to be 35 trillion won by 2014 and 57 trillion won by 2020, which is expected to show an annual average growth rate of 7.6%. The domestic probiotic market is expected to reach 150 billion won by 2014, but the market is growing rapidly, with a 250% growth rate from 2013.
Since the technology for detecting and evaluating immune control probiotics such as allergy suppression has not yet been established, it is expected that if a systematic in vitro experiment or an in vivo experimental mimic screening system is developed and its technology is used well, The value is also expected to be enormous.
Studies on the fundamental mechanism of probiotics are inadequate, and most of the research has been done in vitro . In other words, despite the oral ingestion of probiotics, most of the previous studies have been focused on in vitro experiments using cell lines, and these experimental methods have not been able to replace the research on the functions that can be shown by people taking probiotics There are big disadvantages. In addition, the intestinal immune system (GALT) exposed to probiotics exhibits immune function of probiotics by the simultaneous presence of various immune cells and interaction, but the in vitro experiment is different from the in vivo environment.
Thus, in the present invention, the in vivo system by evaluating the effect of Lactobacillus pento suspension (Lactobacillus pentosus) of these were directly isolated from the mice to different immune cells in order to evaluate the anti-allergic activity of the bacterial strains isolated from Korean traditional food A close study result was derived.
Currently, the evaluation of immunity control for overseas probiotics is applied to various disease animal models, and the results are also increasing at a rapid pace every year. In addition to targeting inflammatory response inhibition of inflammatory diseases such as
Since most probiotics are derived from human intestines or foods, there is an advantage in that there is no major problem in proving stability with other chemical agents once the efficacy has been demonstrated using animal models. In recent years, the therapeutic effect of probiotics as an immunomodulatory agent has been verified through various clinical trials. Many diseases such as asthma, ulcerative colitis, and arthritis have been tried, and clinical trials and studies on atopy have been accelerated In fact.
According to industrialization trend analysis, it is leading the development of probiotics in Europe, which is traditionally strong, and the development and commercialization of functional probiotics are being actively carried out in the US and Japan recently. VSL3 # was developed by VSL Pharmaceutical company in Canada and is currently active in the global market. Recently, VSL3 # has been marketed as an immunity regulator in the domestic market.
The present inventors have made extensive efforts to develop probiotics for the prevention or treatment of allergic and inflammatory diseases caused by Th1, Th17, or Th2 immune responses. As a result, a novel Lactobacillus pentosus strain having antiallergic and anti-inflammatory activity was selected from kimchi, which is a traditional fermented food, and when the strain was treated, regulatory T cell induction, regulatory B cell induction, (Th1-related cytokine, Th17-related cytokine (IL-10), and anti-inflammatory cytokine) in the regulation of the ratio of immunotolerant cytokine (IL-10; antiinflammatory cytokine) to cytokine Inhibiting the production of cytokines, cytokines, and Th2-related cytokines, and enhancing intestinal immune responses, thereby effectively controlling allergy and inflammation.
Accordingly, the present invention provides a Lactobacillus pentosus KF340 strain (Accession No. KCCM 11675P) having a preventive, ameliorating, or therapeutic activity of a Th1-mediated immune disease, a Th17-mediated immune disease or a Th2- The purpose is to provide.
The present invention also relates to the use of the Lactobacillus pentosus KF340 strain (Accession No. KCCM 11675P) as an active ingredient for the prevention of a Th1-mediated immune disease, a Th17-mediated immune disease, or a Th2- The present invention provides a composition for improving, treating, or ameliorating a disease or disorder.
However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.
According to an aspect of the present invention as described above, the present invention Th1- mediated immune diseases, Th17--mediated immune diseases, or Th2- mediated prevention of autoimmune diseases, the novel Lactobacillus pento suspension having an improved or therapeutic activity (Lactobacillus pentosus KF340 strain (Accession No. KCCM 11675P).
The present invention also provides a method of preventing, ameliorating, or treating a Th1-mediated immune disease, a Th17-mediated immune disease, or a Th2-mediated immune disease, comprising the above-mentioned Lactobacillus pentosus KF340 strain (Accession No. KCCM 11675P) ≪ / RTI >
In one embodiment of the present invention, the strain is characterized by being isolated from the kimchi.
In another embodiment of the present invention, the strain may be a live or dead strain.
In another embodiment of the invention, the composition is capable of inducing regulatory T cells.
In another embodiment of the invention, the composition is capable of inducing regulatory B cells.
In another embodiment of the present invention, the composition may make the ratio of IL-10 production to IL-12 production be 5-30.
In another embodiment of the present invention, the composition may inhibit the production of immunoglobulin E (IgE).
In another embodiment of the present invention, the composition may inhibit Th1, Th17, or Th2 related cytokine production.
In another embodiment of the present invention, the composition may enhance the glandular immune response.
In another embodiment of the present invention, the ThI-mediated disease or Th17-mediated immune disease may be a transplant rejection, autoimmune disease, or inflammatory disease.
In another embodiment of the present invention, the Th2-mediated immune disease may be an allergic disease. The above-mentioned allergic diseases are specifically exemplified by food allergies, bronchial asthma, allergic rhinitis (acute or chronic), atopic dermatitis, allergic conjunctivitis, allergic otitis media, urticaria and anaphylactic shock, contact hypersensitivity, allergic contact dermatitis, Bacterial allergies, fungal allergies, virus allergies, drug allergies, thyroid and allergic encephalitis.
In another embodiment of the present invention, the composition may be a pharmaceutical, food, health functional food, cosmetic, or feed composition.
The present invention also relates to a method of treating or preventing a Th1-mediated immune disease, a Th17-mediated immune disease, or a Th2-mediated disease, comprising administering to a subject a composition comprising an Lactobacillus pentosus KF340 strain (Accession No. KCCM 11675P) Thereby providing a method for preventing or treating immune diseases.
In addition, the present invention provides a preventive or therapeutic use of a composition comprising an Lactobacillus pentosus KF340 strain (Accession No. KCCM 11675P) as an active ingredient for a Th1-mediated immune disease, a Th17-mediated immune disease, or a Th2- do.
The novel Lactobacillus pentosus KF340 strain (Accession No. KCCM 11675P) according to the present invention is a novel strain of Lactobacillus pentosus KF340 (Accession No. KCCM 11675P) in accordance with the present invention is an immunostimulatory cytokine (IL-10; antiinflammatory) against regulatory T cell and regulatory B cell induction, immunostimulatory cytokine Cytokine), suppression of the production of immunoglobulin E (IgE), suppression of Th1-related cytokine, Th17-related cytokine, and Th2-related cytokine production during immune hypersensitivity reaction, and enhancement of intestinal immune response by IgA secretion Allergic and inflammatory diseases, and is useful as a composition for preventing, improving or treating a Th1-mediated immune disease, a Th17-mediated immune disease, or a Th2-mediated immune disease, more preferably an allergic or inflammatory disease It is expected to be possible.
FIG. 1 shows the results of measurement of the expression of Foxp3 by co-culture of Lactobacillus pentosus KF340 and immune cells.
FIGS. 2A to 2D are the results showing the effect of oral administration of Lactobacillus pentosus KF340 on the atopic dermatitis in mice induced atopic dermatitis. FIG. 2A shows changes in ear thickness, FIG. 2B shows changes in ear thickness, FIG. 2c is a photograph of a mouse ear, which is a lesion of atopic dermatitis, and FIG. 2d is a result of observing epithelial cell thickness and inflammatory cell infiltration by staining the lesion with H & E or TB.
FIG. 3A shows the results of IL-4 secretion from lymphocytes isolated from each lymph node after oral administration of Lactobacillus pentosus strain KF340 in a mouse induced atopic dermatitis (PP: Payer's patch, mLN: mesenteric lymph node, dLN: draining lymph node), and FIG. 3B shows the result of measuring the expression of GATA-3, a transcription factor of Th2, in the lesion tissue.
4A to 4D are graphs showing the effect of oral administration of Lactobacillus pentosus KF340 live bacteria or dead bacteria in a mouse causing atopic dermatitis. Fig. 4A is a result of measurement of change in ear thickness, (PBS: control group, 340: live cells, HK340: dead cells). FIG. 4 (c) shows the results of measurement of the amount of IL-17A secreted by Th17 And the expression of ROR gamma t.
FIG. 5A shows the increase in IL-10 secretion by Lactobacillus pentosus KF340 in splenocytes, FIG. 5B shows the increase in B cell activity in spleen by the strain treatment, FIG. Indicating the increase in the population of B220 + CD5 + CD1d + B10 cells by the strain treatment.
FIG. 6 shows the results of measurement of the expression of B220 + CD5 + CD1d + by Lactobacillus pentosus KF340 in a mouse model of atopic dermatitis (SPL: spleen, PP: Payer's patch).
FIG. 7 is a graph showing the frequency of dendritic cells (DCs) in the Payer's patch after administration of the Lactobacillus pentosus KF340 strain in the atopic dermatitis mouse model and the decreased expression of CD80 and CD86 in dendritic cells.
8a and 8b show the direct effect of Lactobacillus pentosus KF340 on dendritic cells (DCs). FIG. 8a shows the effect of IL-12 on bone marrow dendritic cells (BMDC) 10 and TGF-?, And FIG. 8b shows the results of measurement of BAFF mRNA expression in dendritic cells (DC) or Payer's patch.
FIG. 9A shows the result of measuring the amount of IgA in the mice that had induced atopic dermatitis before the administration of the Lactobacillus pentosus KF340 strain (0 W) and the end of the experiment (8 W) after the administration, and FIG. The results are shown in Fig.
FIG. 10 is a diagram showing an experimental method and schedule for producing a food allergy mouse model. FIG.
Figs. 11A to 11C show the results of inhibiting the food allergic activity of Lactobacillus pentosus KF340 strain. Fig. 11A is a rectal temperature change, Fig. 11B is a diarrhea reaction, and Fig. 11C is an anaphylactic measurement result.
FIG. 12 shows the results of oral administration of Lactobacillus pentosus KF340 in the contact dermatitis mouse model.
The present inventors have made extensive efforts to develop probiotics for the prevention or treatment of allergy and inflammatory diseases, diseases or conditions induced by Th1 or Th2 immune responses. As a result, a novel Lactobacillus pentosus strain having antiallergic and anti-inflammatory activity was selected from kimchi, which is a traditional fermented food, and when the strain was treated, regulatory T cell induction, regulatory B cell induction, (Th1-related cytokine, Th17-related cytokine (IL-10), and anti-inflammatory cytokine) in the regulation of the ratio of immunotolerant cytokine (IL-10; antiinflammatory cytokine) to cytokine Inhibition of the production of cytokines, cytokines, and Th2-related cytokines, and enhancement of the intestinal immune response, thereby effectively controlling allergies and inflammation.
Accordingly, the present invention provides a novel Lactobacillus pentosus KF340 strain (Accession No. KCCM 11675P) having a preventive, ameliorative or therapeutic activity against a Th1-mediated immune disease, a Th17-mediated immune disease or a Th2- Lt; / RTI >
The present invention also relates to a method for the prevention and / or amelioration of a Th1-mediated immune disease, a Th17-mediated immune disease, or a Th2-mediated immune disease comprising the above-mentioned Lactobacillus pentosus KF340 strain (Accession No. KCCM 11675P) Or a therapeutic composition.
As used herein, the term " prevention " refers to any action that inhibits or delays the development of a Th1-mediated immune disease, a Th17-mediated immune disease, or a Th2-mediated immune disease by administration of a composition according to the present invention do.
As used herein, the term "improvement" means all actions that at least reduce the degree of symptom associated with the condition being treated. Wherein the composition can be used simultaneously or separately with a medicament for treatment before or after the onset of the disease for the prevention or amelioration of a Th1-mediated immune disease, a Th17-mediated immune disease, or a Th2-mediated immune disease .
The term " treatment ", as used herein, refers to any action by the administration of a composition according to the present invention that alleviates or alleviates symptoms of a Th1-mediated disease, a Th17-mediated immune disease, or a Th2- it means.
As used herein, the term " comprising as an active ingredient " is meant to include an amount sufficient to achieve efficacy or activity of the above-mentioned Lactobacillus pentosus KF340 strain. Since the Lactobacillus pentosus KF340 strain of the present invention is a microorganism strain isolated from a food, preferably Kimchi, there is no adverse effect on the human body even when administered in an excessive amount, and the quantitative upper limit of the strain of the present invention is within the appropriate range As shown in FIG.
The Lactobacillus pentosus KF340 strain of the present invention is a strain isolated from kimchi, and the strain may be live or dead.
According to one embodiment of the invention, the composition of the present invention is capable of inducing regulatory T cells. The regulatory T cell induction can be confirmed by increased Foxp3 expression, a regulatory T cell transcription factor, as demonstrated in the Examples below.
In one embodiment of the invention, the composition of the present invention increases 2-20, 5-20, 5-15, 5-10, or 7-9 fold activation of regulatory T cells compared to negative control (See Example 3).
According to one embodiment of the invention, the composition of the invention can induce regulatory B cells. The regulatory B cell induction can be confirmed by increasing the expression of B220 + CD5 + CD1d + B cells (B10 cells) as demonstrated in the following examples. B10 cells are a subset of B cells known to have an anti-inflammatory cytokine, IL-10 producing activity, and play an important role in regulating inflammatory and autoimmune responses.
In one embodiment of the present invention, induction of dendritic cells (DCs) of Payer's patch in which Lactobacillus pentosus KF340 is absorbed into inhibitory dendritic cells promotes the production of IL-10 and BAFF, And directly induced regulatory B cells (see Example 6). The composition of the present invention increases 2-20 fold, 2-10 fold, 2-8 fold, 3-7 fold, or 4-6 fold activation of regulatory B cells compared to negative control.
According to one embodiment of the present invention, the composition of the present invention may increase IL-10 production. IL-10 secretes macrophages and monocytes and T-cell lymphocyte replication and inflammatory cytokines (IL-1, TNF-α, TGF-β, IL-6, IL-8 and IL-12) An increase in IL-10 as an anti-inflammatory cytokine produced by inhibitory lymphoid cells inhibits the inflammatory response.
In one embodiment of the present invention, co-culture of mesenteric lymph node lymphocyte and Lactobacillus pentosus KF340 strain showed that the amount of IL-10 produced by the strain was significantly increased in the lymphocytes. Therefore, the composition of the present invention can make the ratio of the IL-10 production amount to the IL-12 production amount to 5-30, more preferably the ratio of the IL-10 production amount to the IL-12 production amount is 10-30, -30 or 20-30 (see Example 3-1).
According to one embodiment of the present invention, the composition of the present invention can inhibit IgE production. IgE is an immunoglobulin E, which has an affinity for mucous cells or basophils in the blood, and causes an inflammatory reaction when IgE antibodies attached thereto and the corresponding antigens (allergens) react with each other. That is, IgE is an antibody that induces anaphylactic or inflammatory reaction due to allergy. If the IgE production is inhibited, allergic reaction or inflammatory reaction is suppressed.
According to one embodiment of the present invention, the composition of the present invention can inhibit Th1-associated cytokine production. Thus, the compositions of the present invention can be used for the prevention, amelioration or treatment of various Th1-mediated immune diseases, diseases or conditions.
As used herein, the term "Th1 cell" refers to a subset of helper T cell lymphocytes that are specified in terms of gene expression, protein secretion, and functional activity. For example, Th1 cells express a cytokine expression pattern that produces IL-2 and IFN-y but not IL-4, IL-5, IL-10 and IL-13. Th1 cells are involved in cell-mediated immune responses, organ-specific autoimmune diseases and delayed hypersensitivity reactions to a variety of intracellular pathogens.
The term "Th1-mediated immune disorder" as used herein refers to cytokines (Th1-associated cytokines) produced by the production and / or activity of Th1 cells such as IL-1β, IL-2, -γ or TNF-α. The Th1-mediated immune disorder may be a transplant rejection, an autoimmune disease, or an inflammatory disease, and more particularly, a disease selected from the group consisting of colitis, inflammatory bowel disease,
According to one embodiment of the present invention, the composition of the present invention can inhibit Th17-related cytokine production. Thus, the compositions of the present invention can be used for the prevention, amelioration or treatment of various Th17-mediated immune diseases, diseases or conditions.
As used herein, the term "Th17 cell" refers to a subset of helper T cell lymphocytes that are specified in terms of gene expression, protein secretion, and functional activity. For example, Th17 cells are induced by TGF- [beta], IL-6 or IL-21 to produce IL-17, IL-22 and IL-21, but not IL-2, IL-4, -13 does not produce a cytokine expression pattern. Th17 cells have been reported to play a direct role in inflammation and autoimmune pathogenesis and to induce host defense or an abnormal immune response to the pathogen.
The term "Th17-mediated immune disease" as used herein means a disease involving a cytokine (Th17-related cytokine) such as IL-17 produced by the production and / or activity of Th17 cells. Preferably, the Th17-mediated immune disease may be a transplant rejection, an autoimmune disease or an inflammatory disease. More specifically, the Th17-mediated immune disease may be an inflammatory disease such as rheumatoid arthritis, psoriasis, multiple sclerosis, colitis, inflammatory bowel disease, But is not limited to, an immune disorder.
According to one embodiment of the present invention, the composition of the present invention can inhibit Th2-related cytokine production. Thus, the compositions of the present invention can be used for the prevention, amelioration or treatment of various Th2-mediated immune diseases, diseases or conditions. According to another embodiment of the present invention, the composition of the present invention may inhibit cytokine production selected from the group consisting of IL-4 and IL-13.
The term " Th2 cell " as used herein refers to a subset of helper T cell lymphocytes that are specified in terms of gene expression, protein secretion, and functional activity. For example, Th2 cells express IL-4, IL-5 and IL-13 cytokines (Th2-related cytokines) expression patterns, and Th2 cells are involved in humoral immune responses.
As used herein, the term " Th2-mediated immune disease " means a disease involving IgE and mast cells due to the production and activity of allergen-specific Th2 cells, preferably an allergic disease. More specifically, the above-mentioned allergic diseases are selected from food allergies, bronchial asthma, allergic rhinitis (acute or chronic), atopic dermatitis, allergic conjunctivitis, allergic otitis media, urticaria and anaphylactic shock, contact hypersensitivity, , Bacterial allergy, fungal allergy, virus allergy, drug allergy, thyroid and allergic encephalitis.
In one embodiment of the present invention, cytotoxicity of the Lactobacillus pentosus KF340 strain of the present invention to the mouse causing atopic dermatitis was measured and the cytokine changes were measured from lymphocytes isolated from inflammatory lymph nodes. As a result, the Th1-related cytokine IL-4 and IL-13, which mediate IgE secretion, were induced by inducing degranulation of mast cells with IFN-y, Th17-related cytokines IL-17 and Th2-related cytokines (Example 5- 3).
According to one embodiment of the present invention, the composition of the present invention can promote a glandular immune response.
In one embodiment of the present invention, when mice were infected with atopic dermatitis at
The term " allergy " as used herein refers to various diseases, diseases or abnormal conditions caused by hypersensitivity to any substance in the human body, i.e., excessive reaction of the body's immune system to an exogenous substance. The allergic diseases to be applied to the composition of the present invention are preferably Type I immediate hypersensitivity reaction and Type IV delayed hypersensitivity reaction. Type I immediate hypersensitivity reactions are bronchial asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, allergic otitis media, urticaria and anaphylatic shock, Type IV delayed hypersensitivity reactions are contact hypersensitivity , Allergic contact dermatitis, bacterial allergies, fungal allergies, viral allergies, drug allergies, thyroiditis and allergic encephalitis. The type I immediate-type hypersensitivity reaction is divided into two stages. The first step is to suppress the secretion of IgE and IgG1 by the invasion of the allergen and the Th1 cell reaction to produce IL-12 and IFN-γ which increase secretion of IgG2a And IL-4, IL-5, and IL-13, the IL-4 and IL-13 are secreted by the excessive immune response of Th2, The IgE-specific antibodies produced are attached to the surface of mast cells and basophils, so that allergic inflammation is prepared. It has been sensitized to allergens. The second stage of the allergic manifestation is divided into an initial reaction and a late reaction. Allergens re-enter the body to stimulate mast cells and induce a degranulation reaction, which causes release of histamine, lipid metabolites, cytokines, And eosinophil, eosinophil, macrophage, Th2 cell, and basophil are infiltrated into the affected tissue to induce inflammation, resulting in atopic dermatitis, rhinitis, asthma, and the like. Preferably, the allergies of the present invention can be allergic contact dermatitis, allergic atopic dermatitis, or food allergies.
In one embodiment of the present invention, the activity of inhibiting atopic dermatitis, food allergy and contact dermatitis of Lactobacillus pentosus KF340 was confirmed, and it was observed that not only live cells but also heat-treated dead cells exhibited similar effects (Examples 5 and 8 , And 9).
Accordingly, the novel Lactobacillus pentosus KF340 strain of the present invention can be manufactured from a pharmaceutical, health functional food, food, cosmetic, or feed composition.
The pharmaceutical composition of the present invention comprises (a) a pharmaceutically effective amount of the above-mentioned Lactobacillus pentosus of the present invention; And (b) a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically effective amount" means an amount sufficient to achieve the efficacy or activity of the aforementioned Lactobacillus pentosus.
The pharmaceutical composition according to the present invention comprises Lactobacillus pentosus KF340 strain as an active ingredient, and may further comprise a pharmaceutically acceptable carrier. Such pharmaceutically acceptable carriers are those conventionally used in the field of application and include, but are not limited to, saline, sterile water, Ringer's solution, buffered saline, cyclodextrin, dextrose solution, maltodextrin solution, glycerol, ethanol, And may further contain other conventional additives such as antioxidants and buffers as needed. It may also be formulated into injectable formulations, pills, capsules, granules or tablets, such as aqueous solutions, suspensions, emulsions and the like, with the addition of diluents, dispersants, surfactants, binders and lubricants. Suitable pharmaceutically acceptable carriers and formulations can be suitably formulated according to the respective ingredients using the methods disclosed in Remington's reference. The pharmaceutical composition of the present invention is not particularly limited to a formulation, but may be formulated into injections, inhalants, external skin preparations, and the like.
The pharmaceutical composition of the present invention can be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) according to the intended method, but preferably can be administered orally, Depends on the condition and the weight of the patient, the degree of the disease, the type of the drug, the administration route and time, but can be appropriately selected by those skilled in the art.
The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, the term "pharmaceutically effective amount" means an amount sufficient to treat or diagnose a disease at a reasonable benefit / risk ratio applicable to medical treatment or diagnosis, and the effective dose level will depend on the type of disease, severity, The activity of the compound, the sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts. The pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, sequentially or concurrently with conventional therapeutic agents, and may be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.
Specifically, the effective amount of the pharmaceutical composition of the present invention may vary depending on the age, sex, condition, body weight, the degree of absorption of the active ingredient in the body, the rate of inactivation and excretion, the type of disease, 0.001 to 150 mg, preferably 0.01 to 100 mg per kg of body weight, may be administered daily or every other day, or one to three divided doses per day. However, the dosage may be varied depending on the route of administration, the severity of obesity, sex, weight, age, etc. Therefore, the dosage is not limited to the scope of the present invention by any means.
When the composition of the present invention is manufactured from a health functional food composition, the composition may be in the form of tablets, pills, powders, granules, powders, capsules, and liquid formulations, including one or more of carriers, diluents, excipients, ≪ / RTI > Examples of foods that can be added to the composition of the present invention include various foods, powders, granules, tablets, capsules, syrups, drinks, gums, tea, vitamin complexes, and health functional foods. Examples of the additive that can be further included in the present invention include natural carbohydrates, flavors, nutrients, vitamins, minerals (electrolytes), flavors (synthetic flavors, natural flavors and the like), colorants, fillers, At least one component selected from the group consisting of alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, antioxidants, glycerin, alcohols, carbonating agents and fats can be used. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides such as dextrins, cyclodextrins and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. As the above-mentioned flavors, natural flavors (tautatin, stevia extract (for example, rebaudioside A and glycyrrhizin) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used. The composition according to the present invention can be used in various forms such as flavorings such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and heavies, factic acid and its salts, alginic acid and its salts, , pH adjusting agents, stabilizers, antiseptics, glycerin, alcohols, carbonating agents used in carbonated beverages, etc. In addition, the composition of the present invention may contain pulp for the production of natural fruit juices and vegetable drinks. These ingredients may be used independently or in combination. Specific examples of the carrier, excipient, diluent, and additive include, but are not limited to, lactose, dextrose, But are not limited to, calcium carbonate, calcium carbonate, alginate, gelatin, calcium phosphate, calcium silicate, microcrystalline cellulose, It is preferable to use at least one selected from the group consisting of sugar syrup, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
When the antiallergic composition comprising an active ingredient of the Lactobacillus pentosus KF340 strain of the present invention is prepared from a cosmetic composition, it contains components commonly used in cosmetic compositions in addition to Lactobacillus pentosus as an active ingredient, , Customary adjuvants such as solubilizers, vitamins, pigments and flavoring agents, and carriers.
The cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.
When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, or ethoxylated glycerol fatty acid esters.
When a composition for anti-allergy comprising the active ingredient of the Lactobacillus pentosus KF340 strain of the present invention is prepared from a feed composition, it may be prepared by directly adding Lactobacillus pentosus or an additive usually added in the production of feed have. For example, various nutrients such as vitamins, amino acids and minerals, antioxidants, antibiotics, antibacterial agents and other additives. The shape includes powders, granules, pellets or suspensions, and the like.
When the composition of the present invention is prepared from a feed composition, it may be supplied to the land or aquatic animals singly or in a feed mixture. The feed of the present invention includes, but is not limited to, powdered feed, solid feed, moist pellet feed, dry pellet feed, extruder pellet (EP) feed,
A strain having the preventive, ameliorating, or therapeutic activity of the Th1-mediated immune disease, Th17-mediated disease or Th2-mediated immune disease of the present invention is a Th1-mediated immune disease, a Th17-mediated immune disease or a Th2- The present invention is not limited to the composition for preventing, ameliorating, or treating the disease, and the subject disease is common, so that the common content in relation to the composition is omitted in order to avoid the excessive complexity of the present specification.
Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the following examples.
[ Example ]
Example 1: Isolation and Identification of Strain
The strain was isolated from a kimchi prepared by conventional methods using Lactobacillus MRS agar medium (MRS medium, BD288130, Difco, USA), and the isolated strain was identified through 16S rDNA sequencing. As a result of the identification, the 16s rDNA sequence (the first sequence of the sequence listing) of the strain showed 99.73% homology with the conventional Lactobacillus pentosus JCM1558 (T) strain.
The culture medium for the culture of the strain is MRS medium, the culture conditions are pH 6.5 ± 0.2, temperature incubation at 37 ° C. for 48 hours, oxygen requirement is uniform anaerobic, and preservation of the strain through freeze-drying preservation or cell suspension freezing It is possible. The present inventors named this strain as Lactobacillus pentosus KF340 and deposited it on March 6, 2015 with the deposit number KCCM 11675P at the Korean Microorganism Conservation Center (KCCM), an international microorganism depository institution.
Example 2: Preparation and method of experiment
2-1. Experimental animal
For this study, wild-type mice (strain No. -C57BL / 6, stock number -000664, the Jackson laboratory) without any genetic modification were used. In addition, genetically modified mice (Foxp3-GFP knock-in mouse, strain name-B6.Cg-Foxp3 tm2Tch / J, STOCK No. -006772, Jackson laboratory) were used to comparatively easily detect the expression level of Foxp3. Since the mouse was constructed based on a wild-type species, the overall genetic information is the same, but when Foxp3 is expressed, EGFP (enhanced green fluorescence protein), which is a molecule capable of emitting a fluorescent signal, is expressed together with the expression of Foxp3 Therefore, the expression level of Foxp3, which is difficult to detect using the mouse, can be comparatively easily detected without using the antibody.
2-2. Immune cell isolation and Lactobacillus With Pentosus Co-culture
After removal of the mesenteric lymph node (MLN) from the mouse, immune cells (mostly lymphocytes) present in the lymph nodes were suspended in single cells and used for the experiment. Because the probiotics present in the intestine are recognized by immune cells present in the intestinal immune system, immune cells suitable for analyzing the characteristics of probiotics are immune cells present in mesenteric lymph nodes. Therefore, the characteristics of Lactobacillus pentosus KF340 were analyzed with the immune cells isolated from the lymph nodes.
For this, immune cells isolated according to the above method and Lactobacillus pentosus KF340 were cultured in a 1:10 ratio, that is, 3x10 6 of immune cells and 3x10 7 cfu of the strain for 72 hours at 37 ° C in a CO 2 incubator. At that time, the antibiotic gentamicin (11811-031, 15 ㎍ / mL, GIBCO) was treated together to prevent the overgrowth of the test strain.
Example 3: Identification of anti-allergic and anti-inflammatory activity
3-1. Cytokine measurement in co-culture solution
ELISA is a method of measuring the amount of an antigen or an antibody using an antigen-antibody reaction using an enzyme as a marker. (Mouse IL-10 ELISA Ready-SET-Go, eBioscience) and IL-12p70 (Mouse IL-12p70 ELISA Ready-SET) were used to measure the amount of cytokine present in the supernatant after co- -Go, eBioscience) ELISA. The antibody for coating, which detects each cytokine, was treated in 96-wells, and then the supernatant was added to allow the reaction to proceed for a predetermined period of time. Then, another detection antibody for detecting each cytokine was treated. At this time, the antibody for detection is bound to the enzyme (HRP), and a color change occurs as a result of an enzyme-substrate reaction by adding an enzyme substrate (Tetramethylbenzidine Substrate Solution, eBioscience). The absolute amount of cytokine can be measured by this indirect method.
IL-10 (interleukin 10) is a representative immune tolerance cytokine. Since IL-12 (interleukin 12) is known as a representative immunologically active cytokine, the absolute / relative amount of two cytokines is determined and lactic acid bacteria having anti- can do. Thus, mesenteric lymph node cells of Foxp3-knockout mice were isolated according to the method of Example 2-2, mixed with each test strain at a ratio of 1:10, and co-cultured. After culturing for 3 days, the culture supernatant was taken and the absolute amount of IL-12p70, an immunologically active cytokine, and IL-10, an anti-inflammatory cytokine, were measured by ELISA (enzyme linked immunosorbent assay) Respectively.
As a result, when the mesenteric lymph node cells and the Lactobacillus pentosus KF340 strain were co-cultured, the relative ratio (lL-10 / IL-12p70) of the amount of lL-10 and IL-12p70 secretion in the lymphocytes was 24.17 As compared with the negative control group. This indicates that Lactobacillus pentosus KF340 has anti-inflammatory activity.
* It is not detectable, and anti-inflammatory activity can not be expected because it secretes a small amount to escape from the detection area.
3-2. Foxp3 Expression measurement
Foxp3 is a transcription factor of regulatory T cells, a subset of T cells that inhibit excessive immunity. Foxp3 expression can be used to determine the distribution of regulatory T cells.
The regulatory T cell is one of a subset of T cells and plays a role in suppressing excessive immune responses unlike other T cells. Since these regulatory T cells inhibit allergic diseases, it is supported by various studies. Therefore, when the test strain and mesenteric lymph node cells are co-cultured, a strain capable of increasing the distribution of regulatory T cells becomes a probiotic having an antiallergic effect There is a high possibility.
Therefore, in order to compare the expression level of surface molecules of mesenteric lymphocytes co-cultured with Lactobacillus pentosus KF340 strain, Foxp3 was assayed by flow cytometry on the mesenteric lymph node cells isolated according to the method of Example 3-1 The expression level of Foxp3 was measured and compared by measuring the expression of GFP signaling when expressed.
As a result, as shown in Fig. 1, the expression level of Foxp3 (12.48%) in the immune cells co-cultured with Lactobacillus pentosus KF340 was increased about 8.43 times as compared with that in the control (1.48%). Thus, it was confirmed that Lactobacillus pentosus KF340 strain has a regulatory T cell inducing activity, thereby inhibiting allergic diseases.
Example 4: Th2 Identification of antiallergic activity by cytokine inhibition
And to evaluate whether Lactobacillus pentosus KF340 exhibits antiallergic activity through inhibition of Th2 cytokine production.
For this purpose, a mixture of OVA (20 μg) and aluminum hydroxide gel (2 mg) was mixed for 30 minutes, and then 100 μl per mouse of 5-week-old female Balb / c mice were intraperitoneally injected twice . The mouse spleen after
As a result, as shown in the following Table 2, it was confirmed that IL-4 production was reduced when Lactobacillus pentosus KF340 strain was treated as compared with the control group. This means that the Lactobacillus pentosus KF340 strain can inhibit the allergic reaction by inhibiting the production of IL-4.
Control group 1: allergen-free experimental group, control group 2: allergen-induced experimental group
Example 5: Anti-atopic Verify Active
5-1. Induction of atopic dermatitis
Lactobacillus pentosus KF340 strain was orally administered to the mouse at 5 x 10 8 CFU / day for 5 weeks or more for 8 weeks. Three weeks after the first oral administration, the ear of the mouse was peeled off with a surgical tape, and 20 μl of 10% DNCB (2,4-dinitrochlorobenzene) and house dust mite mg / mL). One week later, atopic dermatitis was induced by repeating the treatment with 1% DNCB and 20 ㎕ (10 mg / mL) mites once a week for 5 consecutive weeks.
5-2. Ear thickness and histological changes
After the administration of Lactobacillus pentosus KF340 strain to a house dust mite-induced atopic dermatitis mouse model according to the method of Example 5-1, histological changes were measured to evaluate anti-atopic activity. At this time, dexamethasone, a steroid preparation used as a treatment for atopic dermatitis, was used as a positive control.
As a result of measuring the degree of ear thickness change, erythema, edema, and keratinization of the mouse, as shown in FIG. 2A, unlike the PBS control in which PBS was administered after inducing atopic dermatitis, the Lactobacillus pentosus In the case of the group administered with KF340 strain (340), the thickness of the ear was reduced to a level similar to that of the positive control (Dex), and a negative control group , The oral administration group of Lactobacillus pentosus KF340 strain showed a level similar to that of the positive control group.
In addition, as a result of visual observation, it was observed that atopic dermatitis was greatly improved in the group administered with Lactobacillus pentosus KF340 as shown in FIG. 2C. Histological analysis of ear tissue, which is an inflammation site, The epithelial cell thickness of Lactobacillus pentosus KF340 treated group was decreased and the infiltration of inflammatory cells was significantly suppressed compared to the negative control group.
5-3. Cytokine change measurement
For cytological analysis, draining lymphocytes were isolated from draining lymph nodes (surface lymph nodes, axillary lymph nodes, bronchial lymph nodes) of the inflammatory site of the mouse, stimulated with house dust mites, and then expressed as e - ELISA using a cytokine kit from Bioscience.
As a result, as shown in Table 3 below, in the experimental group in which Lactobacillus pentosus KF340 was continuously administered, the amounts of IFN-γ and IL-17A, which are inflammatory cytokines promoting the onset and aggravation of atopic dermatitis, , And secretion of IL-4 and IL-13, which are Th2-related cytokines, was also decreased, confirming that Lactobacillus pentosus KF340 inhibits atopic dermatitis.
In addition, lymphocytes were isolated from Payer's patch (PPs) and mesenteric lymph nodes (GALT) corresponding to gut-associated lymphoid tissue (GALT) and the Th2 cytokine IL-4 As a result, as shown in FIG. 3A, it was confirmed that the amount of IL-4 secretion decreased remarkably, and the expression of GATA-3, a transcription factor of Th2, was significantly decreased in the inflamed ear as shown in FIG. 3B.
5-4. Lactobacillus Pentosus KF340 Dead bacteria Anti-atopic Verify Active
The Lactobacillus pentosus KF340 live bacteria showed anti-atopic activity through Examples 5-2 and 5-3, and it was verified that the dead bacteria of the strain also had the same anti-atopic activity.
To this end, atopic dermatitis mouse model was prepared in the same manner as in Example 5-1, and Lactobacillus pentosus KF340 live cells or the dead cells prepared by heat treatment at 121 ° C for 15 minutes were administered to mice in the same manner.
As a result of measurement of changes in glans of the mice caused by administration of Lactobacillus pentosus KF340 live or dead cells, it was confirmed that the increase in ear thickness was alleviated in all of the live cells and dead cells as compared with the control (PBS) as shown in FIG. Further, as shown in FIG. It was also observed that erythema, edema, keratin and other symptoms were alleviated through ear photographs. It was found that anti-atopic activity was higher in live bacteria than in dead bacteria.
In addition, changes in Th17 cells and IL-17A following the administration of Lactobacillus pentosus KF340 live cells or dead cells were measured. Although T-cell mediated diseases are thought to be caused by Th1 / Th2, Th17 cells that secrete IL-17 have been reported to play an important role in skin immunity. IL-17A is a major cytokine produced in Th17 cells, and plays an important role in the inflammatory response of tissues, and is known to play a role in neutrophils.
As shown in FIG. 4C, the amount of IL-17 produced by the above-mentioned live cells or dead cells was decreased as compared with the control group, and the expression of RORγt, a Th17-related transcription factor, I confirmed it. From the above results, it was found that the live bacteria and dead bacteria of the Lactobacillus pentosus KF340 strain had atopic dermatitis inhibitory activity through the inhibition of the Th17 immune response.
Example 6: Lactobacillus Pentosus Of KF340 Anti-atopic Active mechanism
6-1. in vitro And in vivo in B220 + CD5 + CD1d + Cell increase confirmation
Since the Lactobacillus pentosus strain KF340 increased the production of IL-10 through the above Example 3-1, the strain affected the cells inducing IL-10 secretion in addition to the regulatory T cells, and thus the anti-allergic activity The cells secreted IL-10 were screened in vitro and in vivo using a flow cytometer (COULTER Epics XL, BECKMAN).
As shown in FIG. 5A, in the in vitro test, the secretion of IL-10 was significantly increased in the spleen by treatment with Lactobacillus pentosus KF340 strain, and the activity was significantly increased in B cells of spleen as shown in FIG. 5B . Furthermore, as shown in FIG. 5C, it was confirmed that the population of B220 + CD5 + CD1d + cells in splenic B cells was significantly increased by the strain treatment.
It has been reported that B10 cells (phenotype: B220 + CD5 + CD1d + or CD19 + CD5 + CD1d +) secrete many IL-10 cytokines specifically in the spleen as a subset of regulatory B cells, It is known to play an important role in regulating inflammatory and autoimmune responses.
In order to verify the above result, the mouse model of atopic dermatitis produced in Example 5-1 was orally administered to a strain of Lactobacillus pentosus KF340, and the spleen of the mouse was isolated and monoclonalized and analyzed by flow cytometry to obtain B220 + CD5 + CD1d + Were measured.
As a result, as shown in FIG. 6, the population of B220 + CD5 + CD1d + B cells was significantly increased in the group administered with Lactobacillus pentosus KF340 strain (340) as compared with the negative control (PBS control). However, B220 + CD5 + CD1d + B cells in PPs did not increase, suggesting that this was due to the systemic action of Lactobacillus pentosus KF340.
6-2. Lactobacillus Pentosus DC induction confirmation by KF340
As confirmed from the results of Example 6-1, Lactobacillus pentosus strain KF340 increased the population of spleen B220 + CD5 + CD1d + B cells, but it was very unlikely that it acted directly on the spleen, It is possible that it acts on the spleen as a secondary response due to action. To prove this, the cell population in PPs was observed after oral administration of Lactobacillus pentosus KF340 strain to the atopic dermatitis mouse model prepared in Example 5-1.
As a result, as shown in FIG. 7, it was found that the frequency of dendritic cells (hereinafter, DC) in PPs was increased in the group (340) in which the strain was administered compared to the control group (PBS control). Also, it was confirmed that the increased DC showed a pattern in which expression of CD80 and CD86 was decreased.
6-3. Lactobacillus Pentosus By KF340 BAFF Confirmation of expression promotion
The results of Example 6-2 above indicate that inhibitory DCs migrate from lymphoid tissue to the spleen and affect spleen cells, thus direct or indirect effect may have helped induce regulatory B cells, The direct effect of Lactobacillus pentosus KF340 on DC was investigated.
To this end, the above-mentioned strains were treated with bone marrow dendritic cells (BMDC), and the levels of IL-10 and TGF-β, which are related cytokines, and mRNA and protein levels of BAFF, Were measured by Real-time PCR and Western blotting. The primer sequences used in the real-time PCR are shown in Table 4 below.
As a result, as shown in FIG. 8A, mRNA expression and protein production were significantly increased in IL-10 compared with the control group, but no significant difference was observed in TGF-β. However, when BAFF mRNA expression level, which is an important factor in the induction of regulatory B cells, was measured, as shown in Fig. 8B, the expression of KF340 strain was significantly increased in DC compared to the control, The expression of BAFF was also increased in the PPs of the dermatitis mouse model.
Lactobacillus pentosus KF340, which exhibited an anti-atopic effect in the atopic dermatitis model, increased IL-10 secretion by increasing the population of spleen B220 + CD5 + CD1d + B10 cells, a kind of regulatory B cells Respectively. The increase of B10 cells promotes the production of IL-10 and BAFF by inducing DC of PPs absorbed by Lactobacillus pentosus strain KF340 into inhibitory DC, or induces direct B10 cell through lymph node through the splenic junction ≪ / RTI >
Example 7: Lactobacillus Pentosus Confirming KF340's immunity enhancing activity
In order to evaluate whether or not the Lactobacillus pentosus KF340 strain promoted intestinal immunity, mice were treated with atopic dermatitis in the same manner as in Example 5-1, and Lactobacillus pentosus KF340 strain was orally administered, 0.0 > IgA < / RTI > For this, we measured the amount of IL-6, a cytokine that induces the secretion of IgA and IgA in the feces, using mouse IgA quantitation kit from BD after collecting the feces of the mice at the 0th day of the experiment and at the end of the experiment (week 8) Respectively.
As a result, as shown in FIG. 9A, the amount of IgA produced by the administration of Lactobacillus pentosus KF340 strain in the mouse induced atopic dermatitis was increased. In addition, IL-6 measurement revealed that IL-6 production, which induces IgA secretion in the payer's patch, is increased. These results indicate that Lactobacillus pentosus KF340 induces the production of IgA and thus affects mucosal immunity enhancement.
Example 8: Food allergy inhibitory activity
8-1. Food allergy Induction and Lactobacillus Pentosus Administration of KF340
The experimental animals were fed with 5-week-old magnetic BALB / c mice from Orient Bio Inc., and were used for breeding and refining for one week in an experimental animal room. According to the experimental procedure shown in Fig. 10, 100 μl of OVA (20 μg) and Alum (2 mg) mixed solution was intraperitoneally injected first by immunization, and then 14 days later, secondary immunization was carried out by the same method. After 14 days of the second immunization, Lactobacillus pentosus KF340 was administered at a daily dose of 5 × 10 8 CFU / day. At this time, the normal control group (Naive) was administered the same amount of PBS as the suspension solvent instead of the Lactobacillus pentosus KF340 suspension, and the positive control group [PC (daxa)] was administered the immunosuppressant dexamethasone. To induce food allergy, OVA at 50 mg / day / day was orally administered to all groups at intervals of 3 days from the 14th day after the second immunization. After an oral administration of OVA, the anaphylactic reaction and diarrhea reaction, which are food allergy inducing indicators, were observed at intervals of 30 minutes. Changes in rectal temperature were measured at intervals of 20 minutes for 60 minutes.
As a result, as shown in FIG. 11A, when the Lactobacillus pentosus strain KF340 was administered, the rectal temperature remained higher than that of the sham group, and diarrhea and anaphylactic reactions were also observed in the sham group as shown in FIGS. 11B and 11C And Lactobacillus pentosus strain KF340 was found to be effective in alleviating the symptoms of food allergy.
8-2. serum IgE Confirm change
After the end of the experiment, blood was drawn through the mouse orbit, and the serum was separated by centrifugation at 3500 rpm for 10 minutes. The IgE content in the separated serum was measured using a mouse IgE quantitative kit from BD.
As a result, IgE, which is closely related to allergic symptoms, was decreased when Lactobacillus pentosus KF340 strain was administered, as shown in Table 5 below.
8-3. Identification of cytokine changes
After the MLN and spleen were removed from each group of mice, a single cell suspension was seeded at a concentration of 5 × 10 6 in 96-wells, and 20 μg of OVA was treated with cells to confirm the antigen-specific response , And cultured for 72 hours. After culturing for 72 hours, the cytokine present in the supernatant was confirmed by ELISA using a BD cytokine quantitation kit.
As a result, as shown in the following Table 5, when the Lactobacillus pentosus KF340 strain was administered, the secretion of IL-4 and IL-13 inducing IgE production in the MLN culture supernatant was decreased, and the food allergy of Lactobacillus pentosus KF340 Inhibitory activity.
Example 9: Contact dermatitis inhibitory activity
9-1. Contact dermatitis induction and Lactobacillus Pentosus Administration of KF340
Five week old female BALB / c was applied for 1 week and then hair was removed from all the experimental groups except Naive at 0 (Day 0), and 5% TMA solution [acetone and isopropylmyristate] Of 4: 1 (v / v) as a solvent] was applied to perform the first sensitization. After 5 days of sensitization, 10 μl of 5% TMA was sensitized to both ears in all experimental groups except for the normal control (Naive), and 10 μl of 2% TMA was applied to both ears at 3 days. The Lactobacillus pentosus KF340 was administered at a concentration of 5 × 10 8 CFU / ml daily after the first sensitization, and only the PBS used to suspend Lactobacillus pentosus KF340 was administered in the same amount as the Shamung group. The positive control group was prednisolone P) was used for the experiment.
TMA is a type of chemical hapten that induces allergic hypersensitivity of immune cells by binding to protein of skin tissue after penetrating into the skin through skin envelope and inducing Th2 reaction strongly and inducing repeated treatment of TMA Site inflammation and tissue thickness increase. As a result of the experiment, as shown in Fig. 12, when the Lactobacillus pentosus KF340 was administered, the thickness of the ear treated with TMA was decreased as compared with the negative control
9-2. serum IgE Confirm change
After the end of the experiment, blood was drawn through the mouse orbit, and the serum was separated by centrifugation at 3500 rpm for 10 minutes. The IgE content in the separated serum was measured using a mouse IgE quantitative kit from BD.
As a result, as shown in Table 6 below, the IgE content exhibiting a high expression in allergic contact dermatitis patients was decreased as compared with the Sham group.
9-3. Identification of cytokine changes
DLN and spleen were removed from each group of mice, and then cultured for 96 hours at 3 × 10 6 cells after single cell suspension. In order to confirm the antigen-specific reaction, the cells were divided into two groups, ie, culturing only the cells and treating 10 μg of the mites. After culturing for 96 hours, the cytokines in the supernatant were quantified using a cytokine quantitative kit of e-Bioscience And confirmed by ELISA method.
As a result, the secretion amount of IL-4, which is a Th2-related cytokine, in DLN decreased, as shown in Table 6, and Lactobacillus pentosus KF340 was found to have an allergic contact dermatitis inhibitory activity.
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. It is therefore intended that the scope of the invention be defined by the claims appended hereto and their equivalents.
<110> KOREA FOOD RESEARCH INSTITUTE <120> Composition for Preventing, Improving, or Treating of Th1-mediated Immune Disease, Th17-mediated Immune Disease, or Th2-mediated Immune Disease Comprising Extracts from Lactobacillus pentosus as an Active Ingredients <130> MP16-217 <150> KR 10-2015-0114938 <151> 2015-08-13 <160> 7 <170> KoPatentin 3.0 <210> 1 <211> 1532 <212> DNA <213> Lactobacillus pentosus KF340 16S rDNA <400> 1 cagagtttga tcatggctca ggacgaacgc tggcggcgtg cctaatacat gcaagtcgaa 60 cgaactctgg tattgattgg tgcttgcatc atgatttaca tttgagtgag tggcgaactg 120 gtgagtaaca cgtgggaaac ctgcccagaa gcgggggata acacctggaa acagatgcta 180 ataccgcata acaacttgga ccgcatggtc cgagtttgaa agatggcttc ggctatcact 240 tttggatggt cccgcggcgt attagctaga tggtggggta acggctcacc atggcaatga 300 tacgtagccg acctgagagg gtaatcggcc acattgggac tgagacacgg cccaaactcc 360 tacgggaggc agcagtaggg aatcttccac aatggacgaa agtctgatgg agcaacgccg 420 cgtgagtgaa gaagggtttc ggctcgtaaa actctgttgt taaagaagaa catatctgag 480 agtaactgtt caggtattga cggtatttaa ccagaaagcc acggctaact acgtgccagc 540 agccgcggta atacgtaagg tggcaagcgt tgtccggatt tattgggcgt aaagcgagcg 600 caggcggttt tttaagtctg atgtgaaagc cttcggctca accgaagaag tgcatcggaa 660 actgggaaac ttgagtgcag aagaggacag tggaactcca tgtgtagcgg tgaaatgcgt 720 agatatatgg aagaacacca gtggcgaagg cggctgtctg gtctgtaact gacgctgagg 780 cttcgaaaag tatgggtcgc aaacaggatt agataccctg gtagtccata ccgtaaacga 840 tgaatgctaa gtgttggagg gtttccgccc ttcagtgctg cagctaacgc attaagcatt 900 ccgcctgggg agtacggccg caaggctgaa actcaaagga attgacgggg gcccgcacaa 960 gcggtggagc atgtggttta attcgaagct acgcgaagaa ccttaccagg tcttgacata 1020 ctatgcaaat ctaagagatt agacgttccc ttcggggaca tggatacagg tggtgcatgg 1080 ttgtcgtcag ctcgtgtcgt gagatgttgg gttaagtccc gcaacgagcg caacccttat 1140 tatcagttgc cagcattaag ttgggcactc tggtgagact gccggtgaca aaccggagga 1200 aggtggggat gacgtcaaat catcatgccc cttatgacct gggctacaca cgtgctacaa 1260 tggatggtac aacgagttgc gaactcgcga gagtaagcta atctcttaaa gccattctca 1320 gttcggattg taggctgcaa ctcgcctaca tgaagtcgga atcgctagta atcgcggatc 1380 agcatgccgc gggtgaatac gttcccgggc cttgtacaca ccgcccgtca caccatgaga 1440 gtttgtaaca cccaaagtcg gtggggtaac cttttaggaa ccagccgcct aacgtgggac 1500 agatgattag ggtgaagtcg taacaaggta cc 1532 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> IL-10 Forward <400> 2 ataactgcac ccacttccca 20 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> IL-10 Reverse <400> 3 tcatttccga taaggcttgg 20 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> TGF-b Forward <400> 4 tggagcaaca tgtggaactc 20 <210> 5 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> TGF-b Reverse <400> 5 tgccgtacaa ctccagtgac 20 <210> 6 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> BAFF Forward <400> 6 aggctggaag aaggagatga g 21 <210> 7 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> BAFF Reverse <400> 7 cagagaagac gagggaaggg 20
Claims (24)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2016/003202 WO2017026620A1 (en) | 2015-08-13 | 2016-03-29 | Composition for preventing, alleviating, or treating th1-mediated immune diseases, th17-mediated immune diseases, or th2-mediated immune diseases, containing, as active ingredient, lactobacillus pentosus |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150114938 | 2015-08-13 | ||
KR20150114938 | 2015-08-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170020204A true KR20170020204A (en) | 2017-02-22 |
KR101761506B1 KR101761506B1 (en) | 2017-07-25 |
Family
ID=58315081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160026193A KR101761506B1 (en) | 2015-08-13 | 2016-03-04 | Composition for Preventing, Improving, or Treating of Th1-mediated Immune Disease, Th17-mediated Immune Disease, or Th2-mediated Immune Disease Comprising Extracts from Lactobacillus pentosus as an Active Ingredients |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101761506B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114657100A (en) * | 2022-04-01 | 2022-06-24 | 江南大学 | Lactobacillus pentosus capable of relieving pathological features of mice infected by influenza virus and application thereof |
KR20220149935A (en) * | 2021-04-30 | 2022-11-10 | 주식회사 레인보우바이오테크 | Probiotics composition comprising lactic acid bacteria isolated from Kimchi and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0124580D0 (en) * | 2001-10-12 | 2001-12-05 | Univ Reading | New composition |
JP5557483B2 (en) | 2009-06-23 | 2014-07-23 | わかもと製薬株式会社 | Lactobacillus strains and foods and pharmaceuticals containing the strains |
FR3004349B1 (en) | 2013-04-15 | 2015-11-27 | Greentech | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF LACTOBACILLUS PENTOSUS |
-
2016
- 2016-03-04 KR KR1020160026193A patent/KR101761506B1/en active IP Right Grant
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220149935A (en) * | 2021-04-30 | 2022-11-10 | 주식회사 레인보우바이오테크 | Probiotics composition comprising lactic acid bacteria isolated from Kimchi and uses thereof |
CN114657100A (en) * | 2022-04-01 | 2022-06-24 | 江南大学 | Lactobacillus pentosus capable of relieving pathological features of mice infected by influenza virus and application thereof |
CN114657100B (en) * | 2022-04-01 | 2023-07-25 | 江南大学 | Lactobacillus pentosus capable of relieving pathological characteristics of influenza virus infected mice and application thereof |
Also Published As
Publication number | Publication date |
---|---|
KR101761506B1 (en) | 2017-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5718917B2 (en) | Novel Lactobacillus plantarum and composition containing the same | |
EP2360237B1 (en) | Novel lactobacillus plantarum and composition containing the same | |
JP5868843B2 (en) | Preparation containing lactic acid bacteria | |
JP5554994B2 (en) | Lactic acid bacteria-containing preparation | |
KR101724126B1 (en) | Composition for Preventing, Improving or Treating of Th1-mediated Immune Disease, Th17-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Lactococcus lactis as an Active Ingredients | |
KR102138832B1 (en) | Lactobacillus Crispatus KBL693 and Use Thereof | |
KR101644595B1 (en) | Lactobacillus paracasei 1- 2- Composition for Preventing Improving or Treating of 1-mediated Immune Disease or 2-mediated Immune Disease Comprising Extracts from and Lactobacillus paracasei as an Active Ingredients | |
ES2407150T3 (en) | Novel lactic acid bacterium with anti-allergic activity, anti-allergic agent, food and pharmaceutical composition comprising, each of them, lactic acid bacteria, and process for the production of the anti-allergic agent | |
US20100143303A1 (en) | Composition comprising lactic acid bacterium having high anti-allergic activity, and method for production of the lactic acid bacterium | |
JP2009142266A (en) | New strain of lactobacillus | |
KR101890428B1 (en) | Composition for Preventing, Improving or Treating of Th1-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Pediococcus pentosaceus as an Active Ingredients | |
KR101644594B1 (en) | Lactobacillus casei 1- 2- Composition for Preventing Improving or Treating of 1-mediated Immune Disease or 2-mediated Immune Disease Comprising Extracts from Lactobacillus casei as an Active Ingredients | |
KR101635997B1 (en) | Pediococcus acidilactici 1- 2- Composition for Preventing Improving or Treating of 1-mediated Immune Disease or 2-mediated Immune Disease Comprising Extracts from Pediococcus acidilactici as an Active Ingredients | |
KR101761506B1 (en) | Composition for Preventing, Improving, or Treating of Th1-mediated Immune Disease, Th17-mediated Immune Disease, or Th2-mediated Immune Disease Comprising Extracts from Lactobacillus pentosus as an Active Ingredients | |
KR102186420B1 (en) | Composition for preventing, improving or treating of allergic diseases comprising Staphylococcus succinus 14BME20 as an active ingredient | |
JP4479162B2 (en) | Immune function regulator and immune function-modulating food | |
KR101959064B1 (en) | Composition for Preventing, Improving or Treating of Th1-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Staphylococcus epidermidis as an Active Ingredients | |
Kang et al. | Induction of Th1 cytokines by Leuconostoc mesenteroides subsp. mesenteroides (KCTC 3100) under Th2-type conditions and the requirement of NF-κB and p38/JNK | |
KR101644593B1 (en) | Anti-Allergic Compositions Comprising Bacillus amyloliquefaciens 26N As Active Ingredients | |
KR20170041337A (en) | Composition for Preventing, Improving or Treating of Th1-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Bacillus amyloliquefaciens subsp. plantarum as an Active Ingredients | |
KR102470357B1 (en) | Composition for enhancing immunity comprising of lactococcus lactis Q1 | |
KR102143615B1 (en) | Novel Kazachstania turicensis CAU Y1706, and compositions using the same | |
EP4368193A1 (en) | Composition for treatment of autoimmune diseases comprising lactobacillus sakei or extracellular vesicles derived therefrom as active ingredient | |
RU2791561C2 (en) | Lactobacillus crispatus kbl693 strain and its application | |
KR20230008619A (en) | Composition for treating autoimmune disease comprising lactobacillus sakei or extracellular vesicle derived therefrom as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |